Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00779194 · ClinicalTrials.gov registry record · Phase 2
Prospective Study of Rapamycin for the Treatment of SLE
A Phase 2 study, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT00779194 is a Phase 2 study that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 99 participants.
The verdict
NCT00779194, a Phase 2 study, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown origin. It involves multiple organs including the joints, skin, kidneys and central nervous system. The disease process is caused by a dysfunction of the immune system. The drugs currently used for the treatment of SLE are only partially effective and carry significant risks for side-effects. Patients that were resistant or intolerant to conventional medication have been effectively treated with Rapamycin and were able to decrease the amount of prednisone they needed. The purpose of this study is to prospectively determine the therapeutic efficacy and mechanism of action of Rapamune in patients with SLE. Healthy subjects not receiving Rapamune will be asked to donate blood to serve as controls only for immunobiological outcomes. As part of the research effort to understand the reason for the variations in the effects of treatment drugs by different individuals, a sub-study of the DNA makeup of subjects enrolled in the trial will also be done. The purpose of the sub-study is to possibly determine whether different responses to the drugs used to treat SLE have a correlation with the differences in the genetic makeup of the subjects.
Interventions
- DRUG Rapamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2008-10 |
| Est. Completion | 2015-12-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00779194
The ClinicalTrials.gov registry entry for NCT00779194 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rapamycin is the first listed.
NCT00779194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00779194 about?
NCT00779194 is a clinical study titled "Prospective Study of Rapamycin for the Treatment of SLE". Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown origin. It involves multiple organs including the joints, skin, kidneys and central nervous system. The disease process is caused by a dysfunction of the immune system. The drugs currently used for the treatment of SLE are only p...
What is the current status of trial NCT00779194?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2008-10. Estimated completion is 2015-12-16.
What interventions are being tested in trial NCT00779194?
The interventions under investigation include: Rapamycin (DRUG).
Who is sponsoring clinical trial NCT00779194?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.